The market for repeat expansion disorders treatment is expected to grow at a CAGR of 13.5% during the forecast period of 2022 to 2030. Repeat expansion disorders are a group of inherited conditions that are triggered by expansions in the DNA repeats of affected individuals. The length of the DNA repeats can range from a single nucleotide all the way up to a dodecamer or even longer. The point at which the repetitive expansions start to cause symptoms differs from one disease to another depending on what it is. These expansions in DNA sequence are now known to be the root cause of over 40 different illnesses. The causal mutations that drive pathogenesis in a substantial number of these disorders have been recognised thanks to remarkable progress that has been made over the past three decades. The expansion of CAG, GCG, CTG, CGG, and CAAA repeats both in coding and non-coding regions in separate genes results in a wide set of disorders with processes associated to protein levels or toxicity, RNA, and/or both. These repeats can be found in either coding or non-coding sequences.
There is a greater than tenfold difference in prevalence based on geographic location, which may be due to differences in case ascertainment and diagnostic criteria. While the populations of Europe, North America, and Australia have a larger incidence, the prevalence among the Asian population has generally been lower. Targeting HD's hyperactive immune system with immunomodulatory medicines is one of the primary focuses of a number of small molecules now undergoing clinical development.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
Increasing Research of Rapid Expansion Disorders Therapies is Boosting the Market
Because of the complexity of repetitive disease genetics and pathobiology, previously unknown commonalities and molecular mechanisms associated with the diseases, such as RNA toxicity, have been uncovered. The investigation of polyglutamine diseases has also shown that post-translational modification is an important step in the pathogenic cascade, and it has demonstrated that the autophagy pathway plays an important role in the degradation of misfolded proteins. These are two themes that are likely to be applicable to the entire field of neurodegeneration. Research on recurrent diseases is yielding insights that are sparking new research avenues. These new lines of inquiry should not only elucidate the molecular mechanisms of disease, but also highlight opportunities for therapeutic intervention in the treatment of conditions that are currently incurable. Despite of these advancements, there arechallenges - just as there were when the science was just starting out - in pinpointing the precise manner in which repetitive expansion mutations lead to inheriteddisorders. As a result, the classification schemes that are currently in use run the risk of becoming obsolete in the near future. In point of fact, a number of discoveries made relatively recently have shed light on the potential complexity of the molecular pathways underpinning the pathogenesis of a variety of diseases caused by repeat expansions. For instance, extensive research into diseases known as CAG-polyglutamine diseases has shown that post-translational modification of disease proteins is an important step in the progression of the disease, and there is now evidence to suggest that the autophagy pathway plays an important part in the breakdown of misfoldedproteins.Market to Present Significant Opportunities During the Forecast Period
Since the first discovery of a novel and obscure type of mutation as the root cause of fragile X syndrome and spinal muscular atrophy (SBMA), a significant amount of progress has been made. The research that has been done in this area has uncovered an extraordinary unanticipated complexity, which includes toxicities that are mediated at the protein, RNA, and genome levels. Research on recurrent diseases, for instance, continues to be one of the most important factors in determining how faulty RNA metabolism and autophagy contribute to human illness. Why the development of relevant treatments has not kept pace with the extraordinary trajectory of scientific advance in the understanding of mechanisms and pathways is an issue that keeps coming up in the field of recurrent disease. This disconnect applies to the vast majority of neurological disorders; nevertheless, repeat diseases present a fantastic potential for the development of reasonable therapies due to the fact that conclusive diagnosis is typically predicated upon repeat allele expansion. These discoveries have also led to some very encouraging therapeutic developments, such as the utilisation of oligonucleotide and morpholino anti-sense repeats targeted against the DM1 CTG expansion.Clinical Trial Process for Lack of Patient Pool Presents Complexities in Designing the Therapies
It is anticipated that factors such as difficulties encountered in the process of designing and performing clinical trials for the development of a treatment for rapid expansion disorders treatment market would be among those that will impede the growth of the market during the forecast period. It is challenging to design clinical trials for rare neurodegenerative diseases for instance, Friedreich's ataxia because there are not enough patients with the disease, the disease is heterogeneous, and it has a slow and variable progression rate. These factors make it difficult to identify reliable outcomemeasures to monitor the progression of the disorders.For instance, Friedreich's ataxia is a genetic, neurodegenerative movement disorder, which, according to an article that was published in the Orphanet Journal of Rare Diseases in August 2020, has a typical age of onset (the age at which the symptoms of a disease first appear) that ranges between 10 and 15 years. This age range was determined by taking the average age of patients diagnosed with Friedreich's ataxia. As a result, it takes a significant amount of time from the disease's onset until it can be properly diagnosed.Huntington Disease Treatment Market Presenting Largest Opportunities
Huntington disease treatment market among other rapid expansion disorders treatment is expected grow the fastest registering a CAGR of 20% during the forecast period 2022 to 2030. It is estimated that important drivers during the forecast period will include the planned label expansion of Ingrezza for the treatment of chorea associated with Huntington's disease, the high burden of HD in western countries, and a robust product pipeline of disease-modifying treatments. There are around 30,000 persons in North America who have HD, and the disease has a prevalence of 5.7 cases per 100,000 people. HD in children is significantly less common than in adults, accounting for only approximately 5 - 10% of all cases. It affects as many as 10 people out of every 1,00,000 people in Europe.There is a greater than tenfold difference in prevalence based on geographic location, which may be due to differences in case ascertainment and diagnostic criteria. While the populations of Europe, North America, and Australia have a larger incidence, the prevalence among the Asian population has generally been lower. Targeting HD's hyperactive immune system with immunomodulatory medicines is one of the primary focuses of a number of small molecules now undergoing clinical development.
North America Remains as the Global Leader and APAC to Present the Largest Opportunity
In 2021, North America held the dominant position in the market for treatments for Huntington's disease, holding a revenue share of 60%. This expansion is due to the high burden of the disease, increased healthcare expenditure, technological advancements, proactive government initiatives, and increased patient awareness about treatments available for rapid expansion disorders treatment. Specifically, the high burden of the disease is causing increased healthcare expenditure.Due to increased product penetration, untapped potential, and the growing prevalence of the conditions in emerging nations throughout the projection period, the market for Huntington's disease treatment is expected to exhibit the highest CAGR in Asia Pacific during the forecast period of 2022 to 2030. It is anticipated that an increasing number of measures being implemented by governments to enhance the health status of the population will fuel the expansion of the market in the region. However, there is a lot of competition in the market for treatments for Huntington's disease, which may slow down its expansion in this region.Intense R &D Focus to Enhance the Market Share of the Market Players
Market is fragmented due to the scope of market that is characterized by different pharma companies leading different therapeutic segment across countries.Therefore, the competition is significantly high and is expected further intensify during the forecast period of 2022 to 2030. The key strategy adopted by Tier 1 companies is focus on R &D to develop novel therapeutic options. Some of the prominent companies dominating the market includes Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc., Larimar Therapeutics, Inc., Healx, Intellia Therapeutics, Inc., Editas Medicine, bluebird bio, Inc., Sanofi, Merck & Co., Inc., H. Lundbeck A/S, Cellectis SA, Bio-Techne, GlaxoSmithKline plc, AllerganAurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd.Cipla Ltd and others.Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Repeat Expansion Disorders Treatment market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Repeat Expansion Disorders Treatment market and their expected impact during the forecast period.
Market Segmentation
Disorders
- Dentatorubral-pallido-luysian atrophy (DRPLA)
- Fragile X syndrome ofmental retardation
- Fragile X tremor ataxia syndrome (FXTAS)
- FRAXE mental retardation (FMR2)
- Spinal and Bulbar Muscular Atrophy/Kennedy's Disease
- type1 (SCA1)
- type 2 (SCA2)
- type 3 (SCA3)
- type 6 (SCA6)
- type 7 (SCA7)
- type 8 (SCA8)
- type 10 (SCA10)
- type 12 (SCA12)
- type 17 (SCA17)
- Huntington's Disease
- Oculopharyngeal musculardystrophy (OPMD)
- Myoclonic epilepsy type 1
- Myotonic dystrophy
- Type 1
- Type 2
- Spinocerebellar ataxia
- Friedreich Ataxia
- Amyotrophic lateral sclerosis (ALS)
- Frontotemporal dementia (FTD).
- Myoclonic epilepsy
- Syndromic / non-syndromicX-linked mental retardation(Gene: ARX)
- Others
Route of Administration
- Oral
- Injectable
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Drug Pipeline (Profile)
- Spinal and Bulbar Muscular Atrophy/Kennedy's Disease
- Huntington's Disease
- spinocerebellar ataxia
- Friedreich Ataxia
- amyotrophic lateral sclerosis (ALS)
- frontotemporal dementia (FTD)
Region Segment (2020 - 2030; US$ Million)
- North America
- U.S.
- Canada
- Rest of North America
- UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa
Global Impact of Covid-19 Segment (2020-2021; US$ Million )
- Pre Covid-19 situation
- Post Covid-19 situation
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Repeat Expansion Disorders Treatment market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Repeat Expansion Disorders Treatment market?
- Which is the largest regional market for Repeat Expansion Disorders Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Repeat Expansion Disorders Treatment market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Repeat Expansion Disorders Treatment market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Repeat Expansion Disorders Treatment Market
2.2. Global Repeat Expansion Disorders Treatment Market, By Disorders, 2021 (US$ Million)
2.3. Global Repeat Expansion Disorders Treatment Market, By Route of Administration, 2021 (US$ Million)
2.4. Global Repeat Expansion Disorders Treatment Market, By Distribution Channel, 2021 (US$ Million)
2.5. Global Repeat Expansion Disorders Treatment Market, By Drug Pipeline (Profile), 2021 (US$ Million)
2.6. Global Repeat Expansion Disorders Treatment Market, By Geography, 2021 (US$ Million)
2.7. Impact of Covid 19
2.8. Attractive Investment Proposition by Geography, 2021
2.9. Competitive Analysis
2.9.1. Market Positioning of Key Repeat Expansion Disorders Treatment Market Vendors
2.9.2. Strategies Adopted by Repeat Expansion Disorders Treatment Market Vendors
2.9.3. Key Industry Strategies
2.9.4. Tier Analysis 2021 Versus 2030
2.10. Key Buying Criteria
2.11. Key Case Reports
2.12. Scenario Analysis
2.12.1. Optimistic estimates and analysis
2.12.2. Realistic estimates and analysis
2.12.3. Pessimistic estimates and analysis
2.13. Market Profiling
2.14. Sales and Marketing Plan
2.15. Top Market Conclusions
2.16. Strategic Recommendations
3. Repeat Expansion Disorders Treatment Market: Business Outlook & Market Dynamics
3.1. Introduction
3.2. Global Repeat Expansion Disorders Treatment Market Value, 2020 - 2030, (US$ Million)
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.2. Market Restraints
3.3.3. Key Challenges
3.3.4. Key Opportunities
3.4. Impact Analysis of Drivers and Restraints
3.5. See-Saw Analysis
3.6. Porter’s Five Force Model
3.6.1. Supplier Power
3.6.2. Buyer Power
3.6.3. Threat Of Substitutes
3.6.4. Threat Of New Entrants
3.6.5. Competitive Rivalry
3.7. PESTEL Analysis
3.7.1. Political Landscape
3.7.2. Economic Landscape
3.7.3. Technology Landscape
3.7.4. Legal Landscape
3.7.5. Social Landscape
3.8. Heptalysis Analysis
3.9. Critical Investigation of Business Problems Through Five Whys Root Cause Analysis & Relevant Solutions
4. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
4.1. Market Overview
4.2. Growth & Revenue Analysis: 2021 Versus 2030
4.3. Market Segmentation
4.3.1. Dentatorubral-pallido-luysian atrophy (DRPLA)
4.3.2. Fragile X syndrome ofmental retardation
4.3.3. Fragile X tremor ataxia syndrome (FXTAS)
4.3.4. FRAXE mental retardation (FMR2)
4.3.5. Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease
4.3.5.1. type1 (SCA1)
4.3.5.2. type 2 (SCA2)
4.3.5.3. type 3 (SCA3)
4.3.5.4. type 6 (SCA6)
4.3.5.5. type 7 (SCA7)
4.3.5.6. type 8 (SCA8)
4.3.5.7. type 10 (SCA10)
4.3.5.8. type 12 (SCA12)
4.3.5.9. type 17 (SCA17)
4.3.6. Huntington’s Disease
4.3.7. Oculopharyngeal musculardystrophy (OPMD)
4.3.8. Myoclonic epilepsy type 1
4.3.9. Myotonic dystrophy
4.3.9.1. Type 1
4.3.9.2. Type 2
4.3.10. Spinocerebellar ataxia
4.3.11. Friedreich Ataxia
4.3.12. Amyotrophic lateral sclerosis (ALS)
4.3.13. Frontotemporal dementia (FTD).
4.3.14. Myoclonic epilepsy
4.3.15. Syndromic / non-syndromicX-linked mental retardation(Gene: ARX)
4.3.16. Others
5. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Oral
5.3.2. Injectable
6. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
7. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2021 Versus 2030
7.3. Market Segmentation
7.3.1. Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease
7.3.2. Huntington’s Disease
7.3.3. spinocerebellar ataxia
7.3.4. Friedreich Ataxia
7.3.5. amyotrophic lateral sclerosis (ALS)
7.3.6. frontotemporal dementia (FTD)8. North America Repeat Expansion Disorders Treatment Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
8.3. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
8.4. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
8.5. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
8.6.Repeat Expansion Disorders Treatment Market: By Region, 2020-2030, USD (Million)
8.6.1.North America
8.6.1.1. U.S.
8.6.1.1.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
8.6.1.1.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
8.6.1.1.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
8.6.1.1.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
8.6.1.2. Canada
8.6.1.2.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
8.6.1.2.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
8.6.1.2.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
8.6.1.2.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
8.6.1.3. Rest of North America
8.6.1.3.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
8.6.1.3.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
8.6.1.3.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
8.6.1.3.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
9. UK and European Union Repeat Expansion Disorders Treatment Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
9.3. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
9.4. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
9.5. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
9.6.Repeat Expansion Disorders Treatment Market: By Region, 2020-2030, USD (Million)
9.6.1.UK and European Union
9.6.1.1. UK
9.6.1.1.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
9.6.1.1.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
9.6.1.1.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
9.6.1.1.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
9.6.1.2. Germany
9.6.1.2.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
9.6.1.2.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
9.6.1.2.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
9.6.1.2.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
9.6.1.3. Spain
9.6.1.3.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
9.6.1.3.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
9.6.1.3.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
9.6.1.3.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
9.6.1.4. Italy
9.6.1.4.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
9.6.1.4.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
9.6.1.4.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
9.6.1.4.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
9.6.1.5. France
9.6.1.5.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
9.6.1.5.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
9.6.1.5.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
9.6.1.5.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
9.6.1.6. Rest of Europe
9.6.1.6.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
9.6.1.6.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
9.6.1.6.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
9.6.1.6.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
10. Asia Pacific Repeat Expansion Disorders Treatment Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
10.3. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
10.4. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
10.5. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
10.6.Repeat Expansion Disorders Treatment Market: By Region, 2020-2030, USD (Million)
10.6.1.Asia Pacific
10.6.1.1. China
10.6.1.1.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
10.6.1.1.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
10.6.1.1.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
10.6.1.1.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
10.6.1.2. Japan
10.6.1.2.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
10.6.1.2.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
10.6.1.2.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
10.6.1.2.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
10.6.1.3. India
10.6.1.3.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
10.6.1.3.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
10.6.1.3.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
10.6.1.3.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
10.6.1.4. Australia
10.6.1.4.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
10.6.1.4.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
10.6.1.4.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
10.6.1.4.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
10.6.1.5. South Korea
10.6.1.5.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
10.6.1.5.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
10.6.1.5.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
10.6.1.5.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
10.6.1.6. Rest of Asia Pacific
10.6.1.6.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
10.6.1.6.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
10.6.1.6.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
10.6.1.6.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
11. Latin America Repeat Expansion Disorders Treatment Market, 2020-2030, USD (Million)
11.1. Market Overview
11.2. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
11.3. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
11.4. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
11.5. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
11.6.Repeat Expansion Disorders Treatment Market: By Region, 2020-2030, USD (Million)
11.6.1.Latin America
11.6.1.1. Brazil
11.6.1.1.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
11.6.1.1.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
11.6.1.1.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
11.6.1.1.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
11.6.1.2. Mexico
11.6.1.2.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
11.6.1.2.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
11.6.1.2.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
11.6.1.2.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
11.6.1.3. Rest of Latin America
11.6.1.3.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
11.6.1.3.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
11.6.1.3.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
11.6.1.3.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
12. Middle East and Africa Repeat Expansion Disorders Treatment Market, 2020-2030, USD (Million)
12.1. Market Overview
12.2. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
12.3. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
12.4. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
12.5. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
12.6.Repeat Expansion Disorders Treatment Market: By Region, 2020-2030, USD (Million)
12.6.1.Middle East and Africa
12.6.1.1. GCC
12.6.1.1.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
12.6.1.1.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
12.6.1.1.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
12.6.1.1.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
12.6.1.2. Africa
12.6.1.2.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
12.6.1.2.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
12.6.1.2.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
12.6.1.2.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
12.6.1.3. Rest of Middle East and Africa
12.6.1.3.1. Repeat Expansion Disorders Treatment Market: By Disorders, 2020-2030, USD (Million)
12.6.1.3.2. Repeat Expansion Disorders Treatment Market: By Route of Administration, 2020-2030, USD (Million)
12.6.1.3.3. Repeat Expansion Disorders Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
12.6.1.3.4. Repeat Expansion Disorders Treatment Market: By Drug Pipeline (Profile), 2020-2030, USD (Million)
13. Company Profile
13.1. Pfizer, Inc.
13.1.1. Company Overview
13.1.2. Financial Performance
13.1.3. Product Portfolio
13.1.4. Strategic Initiatives
13.2. CRISPR Therapeutics
13.2.1. Company Overview
13.2.2. Financial Performance
13.2.3. Product Portfolio
13.2.4. Strategic Initiatives
13.3. Acorda Therapeutics
13.3.1. Company Overview
13.3.2. Financial Performance
13.3.3. Product Portfolio
13.3.4. Strategic Initiatives
13.4. Capsida Biotherapeutics Inc.
13.4.1. Company Overview
13.4.2. Financial Performance
13.4.3. Product Portfolio
13.4.4. Strategic Initiatives
13.5. Larimar Therapeutics, Inc.
13.5.1. Company Overview
13.5.2. Financial Performance
13.5.3. Product Portfolio
13.5.4. Strategic Initiatives
13.6. Healx, Intellia Therapeutics, Inc.
13.6.1. Company Overview
13.6.2. Financial Performance
13.6.3. Product Portfolio
13.6.4. Strategic Initiatives
13.7. Editas Medicine
13.7.1. Company Overview
13.7.2. Financial Performance
13.7.3. Product Portfolio
13.7.4. Strategic Initiatives
13.8. Bluebird bio, Inc.
13.8.1. Company Overview
13.8.2. Financial Performance
13.8.3. Product Portfolio
13.8.4. Strategic Initiatives
13.9. Sanofi, Merck & Co., Inc.
13.9.1. Company Overview
13.9.2. Financial Performance
13.9.3. Product Portfolio
13.9.4. Strategic Initiatives
13.10. H. Lundbeck A/S
13.10.1. Company Overview
13.10.2. Financial Performance
13.10.3. Product Portfolio
13.10.4. Strategic Initiatives
13.11. Cellectis SA
13.11.1. Company Overview
13.11.2. Financial Performance
13.11.3. Product Portfolio
13.11.4. Strategic Initiatives
13.12. Bio-Techne
13.12.1. Company Overview
13.12.2. Financial Performance
13.12.3. Product Portfolio
13.12.4. Strategic Initiatives
13.13. GlaxoSmithKline plc
13.13.1. Company Overview
13.13.2. Financial Performance
13.13.3. Product Portfolio
13.13.4. Strategic Initiatives
13.14. Allergan Aurobindo Pharma Ltd.
13.14.1. Company Overview
13.14.2. Financial Performance
13.14.3. Product Portfolio
13.14.4. Strategic Initiatives
13.15. Sun Pharmaceutical Industries Ltd.
13.15.1. Company Overview
13.15.2. Financial Performance
13.15.3. Product Portfolio
13.15.4. Strategic Initiatives
13.16. Torrent Pharmaceuticals Ltd.
13.16.1. Company Overview
13.16.2. Financial Performance
13.16.3. Product Portfolio
13.16.4. Strategic Initiatives
13.17. Intas Pharmaceuticals Ltd.
13.17.1. Company Overview
13.17.2. Financial Performance
13.17.3. Product Portfolio
13.17.4. Strategic Initiatives
13.18. Cipla Ltd
13.18.1. Company Overview
13.18.2. Financial Performance
13.18.3. Product Portfolio
13.18.4. Strategic InitiativesList of Figures
Figure 1 Global Repeat Expansion Disorders Treatment Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Repeat Expansion Disorders Treatment Market: Quality Assurance
Figure 5 Global Repeat Expansion Disorders Treatment Market, By Disorders, 2021
Figure 6 Global Repeat Expansion Disorders Treatment Market, By Route of Administration, 2021
Figure 7 Global Repeat Expansion Disorders Treatment Market, By Distribution Channel, 2021
Figure 8 Global Repeat Expansion Disorders Treatment Market, By Drug Pipeline (Profile), 2021
Figure 9 Global Repeat Expansion Disorders Treatment Market, By Geography, 2021
Figure 10 Market Geographical Opportunity Matrix - Global Repeat Expansion Disorders Treatment Market, 2021
Figure 11 Market Positioning of Key Repeat Expansion Disorders Treatment Market Players, 2021
Figure 12 Global Repeat Expansion Disorders Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 13 Porters Five Force Model - Current, Midterm and Long Term Perspective
Figure 14 See Saw Analysis
Figure 15 PETEL Analysis
Figure 16 Key Buying Criteria: Current and Long-Term Perspective
Figure 17 Global Repeat Expansion Disorders Treatment Market, Scenario Analysis, 2020 to 2030 (US$ Million)
Figure 18 Heptalysis Analysis: Global Repeat Expansion Disorders Treatment Market
Figure 19 Five Whys Analysis
Figure 20 Global Repeat Expansion Disorders Treatment Market, By Disorders, 2021 Vs 2030, %
Figure 21 Global Repeat Expansion Disorders Treatment Market, By Route of Administration, 2021 Vs 2030, %
Figure 22 Global Repeat Expansion Disorders Treatment Market, By Distribution Channel, 2021 Vs 2030, %
Figure 23 Global Repeat Expansion Disorders Treatment Market, By Drug Pipeline (Profile), 2021 Vs 2030, %
Figure 24 U.S. Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 25 Canada Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 26 Rest of North America Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 27 UK Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 28 Germany Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 29 Spain Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 30 Italy Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 31 France Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 32 Rest of Europe Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 33 China Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 34 Japan Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 35 India Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 36 Australia Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 37 South Korea Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 38 Rest of Asia Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 39 Brazil Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 40 Mexico Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 41 Rest of Latin America Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 42 GCC Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 43 Africa Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
Figure 44 Rest of Middle East and Africa Repeat Expansion Disorders Treatment Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 2 Global Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 3 Global Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 4 Global Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 5 Global Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 6 Global Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 7 North America Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 8 North America Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 9 North America Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 10 North America Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 11 North America Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 12 North America Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 13 U.S. Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 14 U.S. Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 15 U.S. Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 16 U.S. Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 17 U.S. Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 18 U.S. Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 19 Canada Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 20 Canada Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 21 Canada Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 22 Canada Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 23 Canada Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 24 Canada Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 25 Rest of North America Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 26 Rest of North America Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 27 Rest of North America Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 28 Rest of North America Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 29 Rest of North America Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 30 Rest of North America Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 31 UK and European Union Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 32 UK and European Union Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 33 UK and European Union Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 34 UK and European Union Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 35 UK and European Union Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 36 UK and European Union Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 37 UK Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 38 UK Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 39 UK Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 40 UK Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 41 UK Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 42 UK Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 43 Germany Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 44 Germany Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 45 Germany Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 46 Germany Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 47 Germany Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 48 Germany Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 49 Spain Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 50 Spain Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 51 Spain Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 52 Spain Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 53 Spain Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 54 Spain Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 55 Italy Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 56 Italy Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 57 Italy Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 58 Italy Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 59 Italy Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 60 Italy Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 61 France Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 62 France Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 63 France Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 64 France Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 65 France Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 66 France Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 67 Rest of Europe Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 68 Rest of Europe Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 69 Rest of Europe Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 70 Rest of Europe Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 71 Rest of Europe Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 72 Rest of Europe Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 73 Asia Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 74 Asia Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 75 Asia Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 76 Asia Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 77 Asia Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 78 Asia Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 79 China Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 80 China Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 81 China Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 82 China Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 83 China Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 84 China Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 85 Japan Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 86 Japan Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 87 Japan Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 88 Japan Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 89 Japan Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 90 Japan Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 91 India Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 92 India Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 93 India Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 94 India Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 95 India Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 96 India Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 97 Australia Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 98 Australia Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 99 Australia Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 100 Australia Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 101 Australia Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 102 Australia Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 103 South Korea Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 104 South Korea Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 105 South Korea Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 106 South Korea Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 107 South Korea Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 108 South Korea Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 109 Latin America Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 110 Latin America Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 111 Latin America Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 112 Latin America Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 113 Latin America Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 114 Latin America Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 115 Brazil Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 116 Brazil Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 117 Brazil Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 118 Brazil Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 119 Brazil Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 120 Brazil Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 121 Mexico Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 122 Mexico Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 123 Mexico Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 124 Mexico Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 125 Mexico Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 126 Mexico Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 127 Rest of Latin America Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 128 Rest of Latin America Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 129 Rest of Latin America Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 130 Rest of Latin America Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 131 Rest of Latin America Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 132 Rest of Latin America Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 133 Middle East and Africa Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 134 Middle East and Africa Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 135 Middle East and Africa Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 136 Middle East and Africa Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 137 Middle East and Africa Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 138 Middle East and Africa Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 139 GCC Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 140 GCC Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 141 GCC Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 142 GCC Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 143 GCC Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 144 GCC Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 145 Africa Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 146 Africa Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 147 Africa Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 148 Africa Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 149 Africa Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 150 Africa Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Table 151 Rest of Middle East and Africa Repeat Expansion Disorders Treatment Market By Disorders, 2020-2030, USD (Million)
Table 152 Rest of Middle East and Africa Repeat Expansion Disorders Treatment Market By Spinal and Bulbar Muscular Atrophy/Kennedy’s Disease, 2020-2030, USD (Million)
Table 153 Rest of Middle East and Africa Repeat Expansion Disorders Treatment Market By Myotonic dystrophy, 2020-2030, USD (Million)
Table 154 Rest of Middle East and Africa Repeat Expansion Disorders Treatment Market By Route of Administration, 2020-2030, USD (Million)
Table 155 Rest of Middle East and Africa Repeat Expansion Disorders Treatment Market By Distribution Channel, 2020-2030, USD (Million)
Table 156 Rest of Middle East and Africa Repeat Expansion Disorders Treatment Market By Drug Pipeline (Profile), 2020-2030, USD (Million)
Companies Mentioned
- Pfizer Inc.
- CRISPR Therapeutics
- Acorda Therapeutics
- Capsida Biotherapeutics Inc.
- Larimar Therapeutics Inc.
- Healx
- Intellia Therapeutics Inc.
- Editas Medicine
- Bluebird bio Inc.
- Sanofi
- Merck & Co. Inc.
- H. Lundbeck A/S
- Cellectis SA
- Bio-Techne
- GlaxoSmithKline plc
- Allergan Aurobindo Pharma Ltd.
- Sun Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Intas Pharmaceuticals Ltd.
- Cipla Ltd
